{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:16:51Z","timestamp":1781839011669,"version":"3.54.5"},"reference-count":30,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,10]]},"DOI":"10.1182\/bloodadvances.2022009066","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T19:04:11Z","timestamp":1681153451000},"page":"5713-5716","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["The race is on: bispecifics vs CAR T cells in B-cell lymphoma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-7769","authenticated-orcid":false,"given":"Ashwath","family":"Gurumurthi","sequence":"first","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason","family":"Westin","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"2Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"},{"name":"3Department of Medicine II, University Hospital, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"2","key":"2023101015204910900_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2023101015204910900_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"2023101015204910900_bib3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10254","key":"2023101015204910900_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"2023101015204910900_bib5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"key":"2023101015204910900_bib6","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/S2152-2650(22)01540-3","article-title":"ABCL-422 subcutaneous epcoritamab in patients with relapsed or refractory large B-cell lymphoma (EPCORE NHL-1): pivotal results from a phase\u00a02 study","volume":"22","author":"Thieblemont","year":"2022","journal-title":"Clinical Lymphoma Myeloma Leukemia"},{"issue":"24","key":"2023101015204910900_bib7","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2023101015204910900_bib8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2022-158406","article-title":"Odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023101015204910900_bib9","article-title":"Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL)","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023101015204910900_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A\u00a0national service for delivering CD19 CAR-Tin large B-cell lymphoma - the UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"2023101015204910900_bib11","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023101015204910900_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"issue":"10","key":"2023101015204910900_bib13","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A\u00a0real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"2023101015204910900_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2023101015204910900_bib15","first-page":"131","article-title":"Long-term (5 year) overall survival in zuma-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large b-cell lymphoma (LBCL)","volume":"57","author":"Jacobson","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 16","key":"2023101015204910900_bib16","article-title":"Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL; ZUMA-7)","volume":"40","author":"Westin","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023101015204910900_bib17","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2022-159702","article-title":"Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) with salvage chemotherapy followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients with relapsed or refractory large B-cell lymphoma (LBCL): primary analysis of the randomized, phase 3 transform study","volume":"140","author":"Abramson","year":"2022","journal-title":"Blood"},{"key":"2023101015204910900_bib18","doi-asserted-by":"crossref","first-page":"909008","DOI":"10.3389\/fimmu.2022.909008","article-title":"Role of bispecific antibodies in relapsed\/refractory diffuse large B-cell lymphoma in the CART era","volume":"13","author":"Gonzalez Barca","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"2023101015204910900_bib19","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023101015204910900_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"2023101015204910900_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"2023101015204910900_bib22","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"10306","key":"2023101015204910900_bib23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"10343","key":"2023101015204910900_bib24","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel\u00a0versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma\u00a0(TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"2023101015204910900_bib25","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023101015204910900_bib26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2023101015204910900_bib27","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large\u00a0B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2023101015204910900_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023101015204910900_bib29","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2022-162594","article-title":"CAR T-cell therapy remain effective in patients with relapse\/refractory B-cell non-Hodgkin lymphoma after bispecific antibodies exposure: results of a lysa study based on the descar-T registry","volume":"140","author":"Crochet","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2023101015204910900_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5713\/2083583\/blooda_adv-2022-009066-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5713\/2083583\/blooda_adv-2022-009066-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:26:51Z","timestamp":1696951611000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/19\/5713\/495269\/The-race-is-on-bispecifics-vs-CAR-T-cells-in-B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":30,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,10,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009066","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}